Your browser doesn't support javascript.
loading
Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.
Amblard, I; Mercier, F; Bartlett, D L; Ahrendt, S A; Lee, K W; Zeh, H J; Levine, E A; Baratti, D; Deraco, M; Piso, P; Morris, D L; Rau, B; Tentes, A A K; Tuech, J-J; Quenet, F; Akaishi, E; Pocard, M; Yonemura, Y; Lorimier, G; Delroeux, D; Villeneuve, L; Glehen, O; Passot, G.
Afiliación
  • Amblard I; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France.
  • Mercier F; Department of Surgical Oncology, University of Montreal, Montreal, Canada.
  • Bartlett DL; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA.
  • Ahrendt SA; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA.
  • Lee KW; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA.
  • Zeh HJ; Department of Surgery, University of Pittsburgh Medical Center Shaydyside Hospital, Pittsburg, USA.
  • Levine EA; Department of Surgical Sciences-Oncology, Wake Forest Baptist Medical Center, Winston Salem, USA.
  • Baratti D; Department of Surgery, Peritoneal Malignancy Program, National Cancer Institute, Milan, Italy.
  • Deraco M; Department of Surgery, Peritoneal Malignancy Program, National Cancer Institute, Milan, Italy.
  • Piso P; Department of Surgical Oncology, Barmherzige Brüder Krankenhaus Regensburg, Germany.
  • Morris DL; Department of Surgery, University of New South Wales, Sidney, Australia.
  • Rau B; Department of Surgical Oncology, Charite Campus Virchow Klinikum University of Berlin, Germany.
  • Tentes AAK; Department of Surgery, Didimotichon General Hospital, Athens/Didimotichon, Greece.
  • Tuech JJ; Department of Surgical Oncology, CHU Charles Nicolle, Rouen, France.
  • Quenet F; Department of Surgical Oncology, Institut du Cancer de Montpellier, France.
  • Akaishi E; Department of Surgical Oncology, Centro de Oncologia Hospital Sirio Libanes, Sao Paulo, Brazil.
  • Pocard M; Department or Surgical Oncology, Hopital Lariboisière, Paris, France.
  • Yonemura Y; Department of Surgical Oncology, Organization to Support Peritoneal Dissemination Treatment, Osaka, Japan.
  • Lorimier G; Department of Surgical Oncology, ICO-Paul Papin, Angers, France.
  • Delroeux D; Department of Surgical Oncology, CHU de Besançon, France.
  • Villeneuve L; University of Lyon 1, EMR 37-38, France; Hospices Civils de Lyon, Unité de Recherche Clinique, Pôle Information Medicale Evaluation Recherche, Lyon, France.
  • Glehen O; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France.
  • Passot G; Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon; University of Lyon 1, EMR 37-38, France. Electronic address: guillaume.passot@chu-lyon.fr.
Eur J Surg Oncol ; 44(9): 1378-1383, 2018 09.
Article en En | MEDLINE | ID: mdl-30131104
ABSTRACT

BACKGROUND:

Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy.

OBJECTIVE:

To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. MATERIAL AND

METHODS:

A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test.

RESULTS:

Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3-26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively.

CONCLUSION:

Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias de los Conductos Biliares / Sistema de Registros / Procedimientos Quirúrgicos de Citorreducción / Hipertermia Inducida Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Eur J Surg Oncol Año: 2018 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias de los Conductos Biliares / Sistema de Registros / Procedimientos Quirúrgicos de Citorreducción / Hipertermia Inducida Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Eur J Surg Oncol Año: 2018 Tipo del documento: Article País de afiliación: Francia